On January 28, 2024, Panbela Therapeutics, Inc. announced the entry into a material definitive agreement with Roth Capital Partners, LLC, acting as the Placement Agent, and certain purchasers. The agreement pertains to a registered public offering of approximately $9.0 million, which includes 794,000 shares of common stock and pre-funded warrants to purchase up to 3,581,000 shares, as well as Class E and Class F common stock purchase warrants to purchase up to an aggregate of 8,750,000 shares of common stock. The offering price is set at $2.06 per share of common stock and associated common warrants, or $2.059 per pre-funded warrant and associated common warrants. The public offering is expected to close on January 31, 2024, subject to customary closing conditions. The common warrants are exercisable upon issuance...Show More

On January 28, 2024, Panbela Therapeutics, Inc. announced the entry into a material definitive agreement with Roth Capital Partners, LLC, acting as the Placement Agent, and certain purchasers. The agreement pertains to a registered public offering of approximately $9.0 million, which includes 794,000 shares of common stock and pre-funded warrants to purchase up to 3,581,000 shares, as well as Class E and Class F common stock purchase warrants to purchase up to an aggregate of 8,750,000 shares of common stock. The offering price is set at $2.06 per share of common stock and associated common warrants, or $2.059 per pre-funded warrant and associated common warrants. The public offering is expected to close on January 31, 2024, subject to customary closing conditions. The common warrants are exercisable upon issuance and will expire five years from the date of issuance, with an exercise price of $2.06 per share. The pre-funded warrants, which will not expire, have an exercise price of $0.001 per share and were offered to purchasers who would otherwise exceed beneficial ownership limits post-offering. The company has also agreed to a 90-day lock-up period post-closing, during which company executives and directors will not sell company securities. The offering is made under a registration statement declared effective by the SEC on January 26, 2024. Panbela intends to use the net proceeds for clinical development of its product candidates, working capital, business development, and other corporate purposes, which may include debt repayment.